Applied BioCode Corporation
6598
Rank in Stocks
#20667
Applied BioCode Corporation specializes in the complete lifecycle—from design... Applied BioCode Corporation specializes in the complete lifecycle—from design and development to manufacturing and commercialization—of multiplex diagnostic testing solutions tailored for the In-Vitro Diagnostics (IVD) market. Among its key offerings are two sophisticated systems: the BioCode MDx 3000, an automated molecular diagnostics platform that streamlines PCR amplification, hybridization, and detection steps; and the BioCode 2500 analyzer, specifically engineered to read barcoded magnetic beads (BMBs) and display their unique identification along with fluorescence intensity. The company also boasts an extensive portfolio of diagnostic assays, including the BioCode SARS-CoV-2 Assay, a high-throughput, automated nucleic acid multiplex test for detecting SARS-CoV-2 genetic material in nasopharyngeal swabs. Other panels comprise BioCode Respiratory Pathogen Panels, capable of simultaneously identifying and differentiating seventeen distinct respiratory pathogens in nasopharyngeal samples, and BioCode gastrointestinal (GI) pathogen panels, which target prevalent GI pathogens such as viruses, bacteria, and parasites responsible for infectious diarrheal diseases. An expanding pipeline of MDx assays for various molecular tests is also under development. Beyond these, Applied BioCode provides specialized reagents like analyte-specific reagents for fungal pathogens, and multiplex kits for human cytokines and chemokines, vital for biomarker identification. For research flexibility, they offer premixed and customizable multiplex kits for mouse models, alongside similar cytokine/chemokine multiplex kits for rat, monkey, canine, and non-human primate studies. Rounding out its comprehensive services, the company supplies its proprietary BMBs, calibration beads, and coupling kits for a wide array of bioassay applications. They also offer ELISA (Enzyme-Linked Immunosorbent Assay), a method for the precise quantification of drug, protein, or antibody levels in biological samples such as cell lysates or serum, in addition to providing full-spectrum assay development services. Applied BioCode Corporation is headquartered in Santa Fe Springs, California.
Share Price
$0.78497481
Last synced: 2026-11-10
Market Cap
$80.71M
Change (1 day)
-0.77%
Change (1 year)
11.35%
Country
Stock data: Financial Modeling Prep·Updated ·Not investment advice·How we calculate this
Trade Applied BioCode Corporation (6598)
Category
Healthcare
Operating Margin for Applied BioCode Corporation (6598)
Operating Margin as of November 2026 TTM: -9.69%
According to Applied BioCode Corporation's latest financial reports, its current operating margin (TTM) is -9.69%. At the end of 2025 the company had an operating margin of -47.00%.
Operating Margin history for Applied BioCode Corporation from 2012 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -9.69% | -79.38% |
| 2025 | -47.00% | -41.93% |
| 2024 | -80.94% | 71.30% |
| 2023 | -47.25% | 1.37% |
| 2022 | -46.61% | -8.12% |
| 2021 | -50.73% | 52.99% |
| 2020 | -33.16% | -87.30% |
| 2019 | -261.20% | -63.75% |
| 2018 | -720.50% | -26.94% |
| 2017 | -986.13% | -40.40% |
| 2016 | -1,654.46% | 73.76% |
| 2015 | -952.17% | -11.17% |
| 2014 | -1,071.91% | 242.30% |
| 2013 | -313.15% | 0.00% |
| 2012 | 0.00% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 15.24% | -101.57% |
US
|
|
| 18.08% | -101.87% |
IE
|
|
| 21.25% | -102.19% |
US
|
|
| 21.05% | -102.17% |
US
|
|
| 28.09% | -102.90% |
US
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Applied BioCode Corporation's operating margin
What is Applied BioCode Corporation's operating margin?
Applied BioCode Corporation's operating margin is -9.69%, as of Nov 2026.
What was Applied BioCode Corporation's operating margin in 2025?
In 2025, Applied BioCode Corporation's operating margin was -47.00%, compared with -80.94% in 2024.
How has Applied BioCode Corporation's operating margin changed since 2020?
From 2020 to 2025, Applied BioCode Corporation's operating margin was highest in 2020 (-33.16%) and lowest in 2024 (-80.94%).
How does Applied BioCode Corporation's operating margin compare with similar companies?
Applied BioCode Corporation's operating margin (-9.69%) is lower than that of all 5 similar companies listed above. The highest among them is Edwards Lifesciences Corporation, with 28.09%.